376:
the globe and evaluates proposals, development partner reports, and recommends the provision of GHITâs investments to the Board. To add another layer of accountability and scientific rigor, External
Reviewers consisting of more than 100 global health experts from around the world provide independent reviews of R&D proposals to the GHIT Fund and its Selection Committee. To further preemptively counter any potential conflicts of interest, all Selection Committee members, including academicians, must declare that they have no relation to proposal applicants or abstain from any decision-making process in the instance when they may.
179:. This committee worked collectively to design the organization based on the idea that new investment and innovation are needed to address some of the worldâs most neglected diseases and that Japan â a leader in health technologies innovation â could be doing more in the global fight against infectious diseases. The launch committee also designed the unique governance model to minimize potential conflicts of interest in investment decision making. In 2013, the GHIT Fund formally launched with an initial commitment of over US$ 100 million. Original Board members included Kiyoshi Kurokawa,
251:
the
European & Developing Countries Clinical Trials Partnership (EDCTP) to support product development research, specifically by co-funding the PZQ4PSAC phase III clinical study, which is sponsored by Merck KGaA and conducted by the Pediatric Praziquantel Consortium. This study provides clinical data and support for registration of a new praziquantel (PZQ) tablet formulation to treat schistosomiasis in preschool-aged children. The GHIT Fund's full investment portfolio, with detailed background on specific development partnerships, is on its website.
359:
partnerships that leverage
Japanese innovation and capacities in pharmaceuticals. Seven of the 24 novel screening programs have advanced into next stage of development; six candidates have successfully achieved first-in-human trials, and two projects have achieved Proof of Concept (Phase II). Approximately 42% of GHITâs investments have been allocated to projects related to malaria, 13% to tuberculosis, and the rest to NTDs. With regard to product type, 71% of investments have been in drugs, 24% in vaccines, and the rest in diagnostics.
310:
phase of work, allowing it to move the most advanced tools out of the lab, and into the hands of those who need them most. The new commitment for GHITâs second phase is double the initial US$ 100 million investment GHIT received when it was created in 2013. Also in June 2016 ten companies joined GHIT, including a full funding partnership with FUJIFILM Corporation, an associate partnership with
118:. It funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. Bill Gates has noted that "GHIT draws on the immense innovation capacity of Japanâs pharmaceutical companies, universities and research institutions to accelerate the creation of new vaccines, drugs and diagnostic tools for global health."
141:
By 2022 (the end of the Fundâs second five-year phase), GHIT aims to bring two of its projects to a stage where a request for regulatory approval is filed. One of the products in the pipeline and among the closest to hitting the market is a pediatric formulation of praziquantel, a drug widely used to
375:
GHITâs
Selection Committee operates separately from the Board of Directors. This is to ensure objectivity, transparency, and accountability of the investment-making and evaluation process. The Selection Committee consists of renowned experts in product development for infectious diseases from across
309:
A replenishment for the GHIT's second five-year phase was initiated in May 2016 as the
Government of Japan announced as part of a G7 Summit communique a US$ 130 million contribution to the GHIT Fund/UNDP. On June 1, 2017 GHIT announced it had secured commitments of over US$ 200 million for its next
250:
Co-funding of projects is another key investment management tool. Candidate products that have achieved proof-of-concept (POC) are required to have a co-funding strategy in place, though GHIT strongly encourages co-funding for the entire portfolio. In
December 2017 GHIT announced a partnership with
246:
The GHIT Fund utilizes private-sector standards for product development (e.g., using typical milestones and stage-gates for timeline management). GHIT invests heavily in management and evaluation of projects and is rigorous about achievement milestones, swiftly terminating non-performers. But while
1057:
286:
By 2015, funding for GHIT increased to US$ 140 million with the addition of new partners and sponsors. New partners Chugai, Sysmex, and the
Wellcome Trust had joined. The Wellcome Trust alone brought in an additional approximately US$ 4.6 million through January 2017. Three additional companies
371:
GHIT is governed and managed by an international Board of
Directors. The Board is responsible for establishing the organizationâs by-laws, providing fiduciary oversight, approving investment recommendations from the Selection Committee, and assessing the Fundâs overall performance. Dr. Kiyoshi
362:
Products resulting from research must be appropriate, effective, affordable, and accessible for the poorest of the poor. In fact, all grant investment proposals must prioritize open innovation and guarantee that products will be developed on a "no gain, no loss" basis, meaning in the poorest
211:
The GHIT Fund invests across four research platforms (Target
Research, Screening, Hit-to-Lead, and Product Development) in R&D partnerships among Japanese pharmaceutical companies and research institutes and universities with non-Japanese research institutes and universities. This gives
133:
The public-private partnership model, the inclusion of a whole pharmaceutical sector and the structure of individual research projects across sectors and national boundaries are all aimed at reducing the R&D risk to any one entity and to ensure that findings are open to all. Another key
358:
GHITâs Phase 2.0 strategic plan anticipates that by the end of FY2022 two products in its pipeline will be approved by a stringent regulatory authority. As of
December 2017 GHIT has invested over of US$ 115 million across four research platforms into more than 60 global product development
1137:; Wittlin, Sergio; Lafuente-Monasterio, Maria; Benito, Francisco Javier Gamo; Alonso, Laura Maria Sanz; Martinez, Maria Santos; Jimenez-Diaz, Maria Belen; Bazaga, Santiago Ferrer; Angulo-Barturen, Iñigo; Haselden, John N; Louttit, James; Cui, Yi; Sridhar, Arun; et al. (2015).
349:
There are currently three levels of pharmaceutical and diagnostic partners - Full partners, Associate partners, and Affiliate partners. Additionally, non-biopharmaceutical companies engage as Sponsors, contributing in-kind services to reduce the overhead expenses of the Fund.
379:
GHITâs Council, which includes participating pharmaceutical companies and government and international funding entities, provides oversight for the Board of Directors and advocates for GHITâs mission. Council members are never involved in operational and/or funding decisions.
195:
In their own words, the vision of the founders of the GHIT Fund is âone in which the crushing burden of infectious disease no longer prevents billions of people in the developing world from seeking the level of prosperity and longevity now common in the industrialized worldâ.
134:
opportunity the GHIT Fund has created has been to help open the doors of Japanâs public and private drug compound libraries to product development partnerships, which makes possible the screening of tens of thousands of drug candidates for potential new treatments.
1133:; Lotharius, Julie; Marsh, Kennan; White, John; Dayan, Anthony; White, Karen L; Njoroge, Jacqueline W; El Mazouni, Farah; Lao, Yanbin; Kokkonda, Sreekanth; Tomchick, Diana R; Deng, Xiaoyi; Laird, Trevor; Bhatia, Sangeeta N; March, Sandra; Ng, Caroline L;
1054:
137:
The participating companies view their investments into neglected diseases through the Fund as a long-term investment into the future, rather than charity. They see the Fund as a necessary catalyst for having allowed them to pursue this line of research.
423:
199:
The Fundâs stated mission is to âto facilitate international partnerships that enable Japanese technology, innovations, and insights to play a more direct role in reducing disparities in health between the rich and the poor of the world.â
154:
and former executive at Eisai Co. Ltd., BT Slingsby â the fund's first CEO and founder of GHIT. A launch committee was set up in 2012 among the Government of Japan's Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare,
1055:
https://www.thestreet.com/story/13596511/3/ghit-fund-welcomes-ten-new-partnerships-with-fujifilm-otsuka-gsk-johnson-johnson-kyowa-hakko-kirin-merck-mitsubishi-tanabe-nipro-sumitomo-dainippon-pharma-and-salesforcecom.html
1053:"GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma And Salesforce.com," The Street, June 5, 2016 <
129:
The GHIT Fund is the first public-private partnership fund to involve a national government, a UN agency, a consortium of pharmaceutical and diagnostics companies, and international philanthropic foundations.
126:, said: "The GHIT Fund has stepped in to provide that incentive in a pioneering model of partnership that brings Japanese innovation, investment and leadership to the global fight against infectious disease."
203:
In keeping with this vision and mission, global health R&D is considered to be a indispensable to the realization of universal health coverage (UHC), for which Japan is a major proponent.
259:
In 2013, the original partners to the Fund initially committed over US$ 100 million over 5 years. Half came from the two Japanese ministries, and the other half came from Japanese pharma
1406:
295:) joined the Fund as sponsors in the summer of 2015 to provide in-kind services in support of the Fundâs work. Yahoo!Japan has co-launched a special joint website with the Fund:
1187:
701:
607:
212:
researchers around the world access to Japanese expertise and investment. The Fund deliberately refers to grants as "investments" and grantees as "development partners."
1326:
1401:
874:
772:
424:"Japanese Global Health Fund Welcomes the Wellcome Trust and Sysmex Corporation as New Funders and ANA, Morrison & Foerster, and Yahoo! Japan as New Sponsors"
1386:
632:
657:
1376:
1396:
1100:
240:
1371:
39:
215:
Investments go to R&D projects that aim to develop new health technologies for infectious diseases. Diseases targeted by the Fund include
1391:
331:
115:
231:. The Fund also works with established product development partnerships such as the Global Alliance for Tuberculosis Drug Development (
35:
280:
243:
to screen the large quantity of potential drug candidates residing in private and public sector chemical compound libraries in Japan.
176:
107:
978:
849:
656:
Daniel Poppy, âGHIT Fund Marks Japanese Government Interest In Exporting Tech for Global Healthâ, Pharm Asia, July 11, 2013, <
1278:
465:
1366:
530:
658:
https://scrip.pharmamedtechbi.com/SC084839/GHIT-Fund-Marks-Japanese-Government-Interest-In-Exporting-Tech-for-Global-Health
1351:
276:
236:
172:
103:
916:
952:
247:
GHIT has a âprivate-sectorâ orientation to the management of investments, there is no expectation of financial return.
228:
34:(GHIT Fund), headquartered in Japan, is an international public-private partnership between the Government of Japan (
448:"2030 CREATING FUTURE: Japan can lead the world in ending infectious diseases," May 9, 2016, The Asahi Shimbun, <
555:
339:
123:
95:
1331:
1003:
79:
17:
488:"The Global Health Innovative Technology (GHIT) Fund: Financing medical innovations for neglected populations"
150:
The idea of a Japanese nonprofit focused on global health R&D was conceived during a conversation between
1381:
1336:
762:
GHIT Fund website: About the GHIT Fund (www.ghitfund.org/about/organization/mission), accessed on 09/30/2014
674:
299:
1221:
1139:"A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria"
311:
87:
1108:
1361:
1356:
1130:
319:
67:
363:
countries drugs will be licensed without royalties, while in others, they will be licensed at cost.
827:
288:
372:
Kurokawa is Chair of the Board and Dr. BT Slingsby is the founding CEO and Executive Director.
1341:
1168:
868:
819:
709:
509:
335:
323:
71:
1346:
1158:
1150:
898:
811:
499:
1200:
1134:
1061:
469:
315:
303:
63:
449:
1246:
1163:
1138:
343:
268:
160:
111:
55:
1074:
734:
504:
487:
1320:
119:
1282:
902:
934:
831:
224:
151:
403:âJapan in pioneering partnership to fund global health researchâ, by Andrew Jack,
1154:
1211:âGive and It Shall Be Given unto Youâ, The Economist, November 16â22, 2013, p.72
1029:
581:
327:
292:
232:
184:
75:
1188:"Tokyo-based fund CEO leads public-private fight against diseases around globe"
702:"Tokyo-based fund CEO leads public-private fight against diseases around globe"
669:âJapan and Partners Team Up to Tackle Neglected Diseasesâ, by Dina Fine Maron,
608:"Tokyo-based fund CEO leads public-private fight against diseases around globe"
462:
180:
713:
633:"Japan-based fund unites public, private sectors to fight infectious disease"
1172:
823:
513:
953:"The GHIT Fund Portfolio | Global Health Innovative Technology Fund"
272:
260:
168:
156:
91:
59:
43:
956:
675:
http://www.scientificamerican.com/article.cfm?id=japan-and-partners-team
935:"Pediatric Praziquantel Consortium - Pediatric Praziquantel Consortium"
220:
461:
See WHO's video featuring Margeret Chan, WHO Director-General, here:
99:
47:
815:
850:"Investing in innovation for health: an interview with BT Slingsby"
264:
164:
83:
51:
1004:"Japan To Contribute US$ 130 Million Replenishment To GHIT Fund"
917:"EDCTP and Global Health Innovative Technology Fund partnership"
531:"Medidata BrandVoice: Investing In Drugs That Won't Make Money"
296:
1309:
216:
1260:
1279:"GHIT Fund | Global Health Innovative Technology Fund"
1247:"GHIT Fund | Global Health Innovative Technology Fund"
142:
schistosomiasis, a disease caused by parasitic flatworms.
979:"Japanese drugmakers get serious about tackling dengue"
422:
Fund), Global Health Innovative Technology Fund (GHIT.
1261:"GHIT Fund - Global Health Innovative Technology Fund"
1075:"GHIT Fund | Global Health Innovative Technology Fund"
735:"GHIT Fund | Global Health Innovative Technology Fund"
481:
479:
477:
450:
http://www.asahi.com/ajw/articles/AJ201605090001.html
1265:
GHIT Fund(Global Health Innovative Technology Fund)
1079:
GHIT Fund(Global Health Innovative Technology Fund)
739:
GHIT Fund(Global Health Innovative Technology Fund)
887:"Joining the Fight Against Neglected Diseases" in
854:Devpolicy Blog from the Development Policy Centre
297:âSave millions of lives from infectious diseasesâ
848:Slingsby, Camilla Burkot, BT (7 December 2015).
686:âJoining the Fight Against Neglected Diseasesâ,
42:), 16 pharmaceutical and diagnostics companies (
797:
795:
556:"The Value of Product Development Partnerships"
18:Global Health Innovative Technology Fund (GHIT)
1407:International medical and health organizations
8:
873:: CS1 maint: multiple names: authors list (
773:"Aiming for truly universal health coverage"
463:https://ghitfund.org/general/eventreport2015
690:magazine, June 7, 2013, Volume 340, p.1148
560:The National Bureau of Asian Research (NBR)
1162:
503:
843:
841:
758:
756:
486:Slingsby, BT; Kurokawa, Kiyoshi (2013).
32:Global Health Innovative Technology Fund
1402:Research institutes established in 2013
939:www.pediatricpraziquantelconsortium.org
785:âGive and It Shall Be Given unto Youâ,
525:
523:
417:
415:
413:
389:
241:Drugs for Neglected Diseases initiative
866:
399:
397:
395:
393:
291:, law firm Morrison Foerster LLP, and
40:Ministry of Health, Labour and Welfare
27:Nonprofit organization in Tokyo, Japan
7:
1387:United Nations Development Programme
332:Mitsubishi Tanabe Pharma Corporation
116:United Nations Development Programme
1377:Bill & Melinda Gates Foundation
1327:Publicâprivate partnership projects
281:Bill & Melinda Gates Foundation
177:Bill & Melinda Gates Foundation
146:Conceptualization and establishment
108:Bill & Melinda Gates Foundation
1186:Otake, Tomoko (12 December 2017).
802:Yamada, T (2013). "Tachi Yamada".
700:Otake, Tomoko (12 December 2017).
606:Otake, Tomoko (12 December 2017).
25:
1397:Organizations established in 2013
122:, former Director-General of the
1101:"ăăŹăčăȘăȘăŒăč - ć
Źç瀟ćŁæłäșșă°ăăŒăă«ăă«ăčæèĄæŻèćșé"
1190:– via Japan Times Online.
903:10.1126/science.340.6137.1148-b
1143:Science Translational Medicine
314:, affiliate partnerships with
1:
1372:Takeda Pharmaceutical Company
804:Nature Reviews Drug Discovery
505:10.1016/S2214-109X(13)70055-X
237:Medicines for Malaria Venture
1392:Organizations based in Tokyo
1228:(in Japanese), 16 March 2023
1155:10.1126/scitranslmed.aaa6645
789:, November 16â22, 2013, p.72
580:Thomas, Ben (10 May 2013).
367:Leadership & Governance
229:neglected tropical diseases
36:Ministry of Foreign Affairs
1423:
342:, and a sponsorship from
340:Sumitomo Dainippon Pharma
124:World Health Organization
1008:Asian Scientist Magazine
492:The Lancet Global Health
897:(6137): 1148â9. 2013.
706:The Japan Times Online
302:9 October 2015 at the
1367:Otsuka Pharmaceutical
1352:Johnson & Johnson
320:Johnson & Johnson
312:Otsuka Pharmaceutical
68:Johnson & Johnson
1131:Phillips, Margaret A
889:"Around the World".
673:, November 8, 2013 (
187:, and Ko-Yung Tung.
1034:firstwordpharma.com
671:Scientific American
239:, and Geneva-based
207:Investment approach
1111:on 1 November 2019
1060:2016-09-18 at the
959:on 1 February 2018
775:. 8 December 2017.
468:2019-11-01 at the
428:www.prnewswire.com
289:All Nippon Airways
279:together with the
191:Vision and mission
96:Sumitomo Dainippon
1285:on 26 August 2018
1149:(296): 296ra111.
582:"Article expired"
336:Nipro Corporation
324:Kyowa Hakko Kirin
80:Mitsubishi Tanabe
72:Kyowa Hakko Kirin
16:(Redirected from
1414:
1313:
1312:
1310:Official website
1295:
1294:
1292:
1290:
1281:. Archived from
1275:
1269:
1268:
1257:
1251:
1250:
1243:
1237:
1236:
1235:
1233:
1218:
1212:
1209:
1203:
1198:
1192:
1191:
1183:
1177:
1176:
1166:
1127:
1121:
1120:
1118:
1116:
1107:. Archived from
1105:www.ghitfund.org
1097:
1091:
1090:
1088:
1086:
1071:
1065:
1051:
1045:
1044:
1042:
1040:
1026:
1020:
1019:
1017:
1015:
1000:
994:
993:
991:
989:
975:
969:
968:
966:
964:
955:. Archived from
949:
943:
942:
931:
925:
924:
913:
907:
906:
885:
879:
878:
872:
864:
862:
860:
845:
836:
835:
799:
790:
783:
777:
776:
769:
763:
760:
751:
750:
748:
746:
731:
725:
724:
722:
720:
697:
691:
684:
678:
667:
661:
654:
648:
647:
645:
643:
629:
623:
622:
620:
618:
603:
597:
596:
594:
592:
577:
571:
570:
568:
566:
552:
546:
545:
543:
541:
527:
518:
517:
507:
483:
472:
459:
453:
446:
440:
439:
437:
435:
419:
408:
401:
255:Funding for GHIT
21:
1422:
1421:
1417:
1416:
1415:
1413:
1412:
1411:
1332:Astellas Pharma
1317:
1316:
1308:
1307:
1304:
1299:
1298:
1288:
1286:
1277:
1276:
1272:
1259:
1258:
1254:
1245:
1244:
1240:
1231:
1229:
1220:
1219:
1215:
1210:
1206:
1201:Open innovation
1199:
1195:
1185:
1184:
1180:
1135:Fidock, David A
1129:
1128:
1124:
1114:
1112:
1099:
1098:
1094:
1084:
1082:
1073:
1072:
1068:
1062:Wayback Machine
1052:
1048:
1038:
1036:
1028:
1027:
1023:
1013:
1011:
1002:
1001:
997:
987:
985:
977:
976:
972:
962:
960:
951:
950:
946:
933:
932:
928:
915:
914:
910:
888:
886:
882:
865:
858:
856:
847:
846:
839:
816:10.1038/nrd4110
801:
800:
793:
784:
780:
771:
770:
766:
761:
754:
744:
742:
733:
732:
728:
718:
716:
699:
698:
694:
685:
681:
668:
664:
655:
651:
641:
639:
631:
630:
626:
616:
614:
612:The Japan Times
605:
604:
600:
590:
588:
586:The Japan Times
579:
578:
574:
564:
562:
554:
553:
549:
539:
537:
529:
528:
521:
485:
484:
475:
470:Wayback Machine
460:
456:
447:
443:
433:
431:
430:(Press release)
421:
420:
411:
405:Financial Times
402:
391:
386:
369:
356:
316:GlaxoSmithKline
304:Wayback Machine
257:
209:
193:
148:
64:GlaxoSmithKline
28:
23:
22:
15:
12:
11:
5:
1420:
1418:
1410:
1409:
1404:
1399:
1394:
1389:
1384:
1382:Wellcome Trust
1379:
1374:
1369:
1364:
1359:
1354:
1349:
1344:
1339:
1337:Daiichi Sankyo
1334:
1329:
1319:
1318:
1315:
1314:
1303:
1302:External links
1300:
1297:
1296:
1270:
1252:
1238:
1213:
1204:
1193:
1178:
1122:
1092:
1066:
1046:
1021:
995:
970:
944:
926:
908:
880:
837:
791:
778:
764:
752:
726:
692:
679:
662:
649:
624:
598:
572:
547:
519:
473:
454:
441:
409:
407:, May 30, 2013
388:
387:
385:
382:
368:
365:
355:
352:
344:Salesforce.com
269:Daiichi Sankyo
256:
253:
208:
205:
192:
189:
161:Daiichi Sankyo
147:
144:
112:Wellcome Trust
56:Daiichi Sankyo
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1419:
1408:
1405:
1403:
1400:
1398:
1395:
1393:
1390:
1388:
1385:
1383:
1380:
1378:
1375:
1373:
1370:
1368:
1365:
1363:
1360:
1358:
1355:
1353:
1350:
1348:
1345:
1343:
1340:
1338:
1335:
1333:
1330:
1328:
1325:
1324:
1322:
1311:
1306:
1305:
1301:
1284:
1280:
1274:
1271:
1266:
1262:
1256:
1253:
1248:
1242:
1239:
1227:
1223:
1217:
1214:
1208:
1205:
1202:
1197:
1194:
1189:
1182:
1179:
1174:
1170:
1165:
1160:
1156:
1152:
1148:
1144:
1140:
1136:
1132:
1126:
1123:
1110:
1106:
1102:
1096:
1093:
1081:(in Japanese)
1080:
1076:
1070:
1067:
1063:
1059:
1056:
1050:
1047:
1035:
1031:
1025:
1022:
1010:. 23 May 2016
1009:
1005:
999:
996:
984:
980:
974:
971:
958:
954:
948:
945:
940:
936:
930:
927:
922:
918:
912:
909:
904:
900:
896:
892:
884:
881:
876:
870:
855:
851:
844:
842:
838:
833:
829:
825:
821:
817:
813:
809:
805:
798:
796:
792:
788:
787:The Economist
782:
779:
774:
768:
765:
759:
757:
753:
741:(in Japanese)
740:
736:
730:
727:
715:
711:
707:
703:
696:
693:
689:
683:
680:
676:
672:
666:
663:
659:
653:
650:
638:
634:
628:
625:
613:
609:
602:
599:
587:
583:
576:
573:
561:
557:
551:
548:
536:
532:
526:
524:
520:
515:
511:
506:
501:
498:(4): e184â5.
497:
493:
489:
482:
480:
478:
474:
471:
467:
464:
458:
455:
451:
445:
442:
429:
425:
418:
416:
414:
410:
406:
400:
398:
396:
394:
390:
383:
381:
377:
373:
366:
364:
360:
353:
351:
347:
345:
341:
337:
333:
329:
325:
321:
317:
313:
307:
305:
301:
298:
294:
290:
284:
282:
278:
274:
270:
266:
262:
254:
252:
248:
244:
242:
238:
234:
230:
226:
222:
218:
213:
206:
204:
201:
197:
190:
188:
186:
182:
178:
174:
170:
166:
162:
158:
153:
145:
143:
139:
135:
131:
127:
125:
121:
120:Margaret Chan
117:
113:
109:
105:
101:
97:
93:
89:
85:
81:
77:
73:
69:
65:
61:
57:
53:
49:
45:
41:
37:
33:
19:
1287:. Retrieved
1283:the original
1273:
1264:
1255:
1241:
1230:, retrieved
1225:
1216:
1207:
1196:
1181:
1146:
1142:
1125:
1113:. Retrieved
1109:the original
1104:
1095:
1083:. Retrieved
1078:
1069:
1049:
1037:. Retrieved
1033:
1024:
1012:. Retrieved
1007:
998:
986:. Retrieved
982:
973:
961:. Retrieved
957:the original
947:
938:
929:
920:
911:
894:
890:
883:
857:. Retrieved
853:
810:(9): 658â9.
807:
803:
786:
781:
767:
743:. Retrieved
738:
729:
717:. Retrieved
705:
695:
687:
682:
670:
665:
652:
640:. Retrieved
636:
627:
615:. Retrieved
611:
601:
589:. Retrieved
585:
575:
563:. Retrieved
559:
550:
538:. Retrieved
534:
495:
491:
457:
444:
432:. Retrieved
427:
404:
378:
374:
370:
361:
357:
348:
308:
285:
258:
249:
245:
225:tuberculosis
214:
210:
202:
198:
194:
152:Tachi Yamada
149:
140:
136:
132:
128:
31:
29:
1362:Merck Group
1357:Kirin Group
1085:17 February
1030:"FirstWord"
983:Nikkei Asia
745:17 February
642:17 February
637:Japan Today
293:Yahoo!Japan
233:TB Alliance
185:Ann Veneman
76:Merck Group
1321:Categories
1289:20 October
1115:31 January
963:9 December
384:References
181:Peter Piot
1226:Knowledge
719:1 January
714:0447-5763
1342:Fujifilm
1173:26180101
1058:Archived
869:cite web
824:23989787
514:25104343
466:Archived
300:Archived
273:Shionogi
261:Astellas
169:Shionogi
157:Astellas
92:Shionogi
60:Fujifilm
44:Astellas
1347:GSK plc
1164:4539048
891:Science
832:2654055
688:Science
221:malaria
106:), the
1232:17 May
1171:
1161:
1039:17 May
1014:17 May
988:17 May
859:17 May
830:
822:
712:
617:17 May
591:17 May
565:17 May
540:17 May
535:Forbes
512:
434:17 May
354:Impact
277:Takeda
275:, and
227:, and
175:, the
173:Takeda
110:, the
104:Takeda
100:Sysmex
88:Otsuka
48:Chugai
1222:"é»ć·æž
"
921:EDCTP
828:S2CID
328:Merck
265:Eisai
165:Eisai
84:Nipro
52:Eisai
1291:2015
1234:2023
1169:PMID
1117:2018
1087:2017
1064:>
1041:2023
1016:2023
990:2023
965:2014
875:link
861:2023
820:PMID
747:2017
721:2018
710:ISSN
660:>
644:2017
619:2023
593:2023
567:2023
542:2023
510:PMID
452:>
436:2023
114:and
102:and
38:and
30:The
1159:PMC
1151:doi
899:doi
895:340
812:doi
500:doi
235:),
217:HIV
1323::
1263:.
1224:,
1167:.
1157:.
1145:.
1141:.
1103:.
1077:.
1032:.
1006:.
981:.
937:.
919:.
893:.
871:}}
867:{{
852:.
840:^
826:.
818:.
808:12
806:.
794:^
755:^
737:.
708:.
704:.
677:)
635:.
610:.
584:.
558:.
533:.
522:^
508:.
494:.
490:.
476:^
426:.
412:^
392:^
346:.
338:,
334:,
330:,
326:,
322:,
318:,
306:.
283:.
271:,
267:,
263:,
223:,
219:,
183:,
171:,
167:,
163:,
159:,
98:,
94:,
90:,
86:,
82:,
78:,
74:,
70:,
66:,
62:,
58:,
54:,
50:,
46:,
1293:.
1267:.
1249:.
1175:.
1153::
1147:7
1119:.
1089:.
1043:.
1018:.
992:.
967:.
941:.
923:.
905:.
901::
877:)
863:.
834:.
814::
749:.
723:.
646:.
621:.
595:.
569:.
544:.
516:.
502::
496:1
438:.
287:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.